Professor Godfrey is an NHMRC Senior Principal Research Fellow, a Fellow of the Australian Academy for Health and Medical Sciences, Past President of the Australasian Society for Immunology and founder and Past President of the Melbourne Immunotherapy Network. His area of interest is the field of unconventional T cells including development, function and therapeutic potential of these cells. In response to COVID-19, he has led a large team of investigators in the development of a vaccine, as well as diagnostic tests, for SARS-CoV-2. The vaccine will be tested in phase I clinical trials later this year. Godfrey has published over 250 scientific papers that have collectively been cited over 36000 times and he is a Clarivate Highly Cited Researcher.